Jelmyto (mitomycin) is used to treat adults with low-grade cancers of the kidney and bladder (upper tract urothelial cancer). It’s a gel that’s placed into the upper urinary tract through a nephrostomy tube or urinary catheter. This medication is given by a healthcare professional at a urology office or clinic, first once a week and then later once a month. Side effects can include side pain and blockage in the urinary tract. You also might notice that the color of your urine is blue or purple after your dose.
Jelmyto (mitomycin) is an alkylating agent. It’s a type of chemotherapy that interferes with your cells’ ability to make DNA and RNA, the genetic material necessary for cell growth and division. By blocking your cells’ ability to make their genetic material, the medication prevents fast-growing cells (like cancer cells) from spreading.
Jelmyto is a gel form of mitomycin that’s given into the urinary tract so that it reaches your kidneys and bladder. The medication stays in the kidneys and bladder, where it works against the cancer cells, for 4 to 6 hours. Over time, the gel turns into liquid that your body gets rid of through your urine.
The following side effects may get better over time as your body gets used to the medication. Let your healthcare provider know immediately if you continue to experience these symptoms or if they worsen over time.
Contact your healthcare provider immediately if you experience any of the following.
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):
Usually, Jelmyto (mitomycin) is given once a week for the first 6 weeks of treatment. Then in a few months, your urologist will have you get scans of your urinary tract done to check how well the medication is working. If Jelmyto (mitomycin) is doing well to fight your cancer, you can continue getting the medication once a month for up to 11 more doses.
Jelmyto is a brand-name product that contains the chemotherapy medication mitomycin in a specific gel form. This gel is made so that it can be given directly into the bladder and urinary tract to treat the cancer there. Jelmyto (mitomycin) isn’t interchangeable with other mitomycin products. This means that you can’t replace Jelmyto (mitomycin) with other mitomycin products like the injection form to treat low-grade upper tract bladder cancer. You also can’t use Jelmyto (mitomycin) to treat other medical conditions.
In clinical studies, the two most common side effects that happened during treatment with Jelmyto (mitomycin) were blockages in the urinary tract and pain in the sides or lower back (flank pain). To prevent these side effects, it’s a good idea to hydrate well and avoid foods and beverages that can irritate the bladder, like caffeine and alcohol. Placing a warm compress to your stomach can help relieve pain while you’re urinating. Talk with your urologist if you’re concerned about side effects with Jelmyto (mitomycin) treatment or if the side effects are negatively affecting your daily life.
In a study of 71 people with low-grade upper tract bladder cancer who were treated with once-weekly Jelmyto (mitomycin), almost 60% had a complete response to the first 6 weeks of treatment. Having a complete response to treatment meant that there was no evidence of bladder cancer on imaging results and on test results of bladder tissue. Speak with your urologist for more information about how well Jelmyto (mitomycin) might work for you.
After each Jelmyto (mitomycin) treatment, you’ll need to take certain safety precautions when you urinate. Be careful not to accidentally get urine anywhere on yourself for at least 6 hours after each dose. Be sure to sit on the toilet to urinate and flush several times after using the toilet. Then after you use the toilet, wash your hands, inner thighs, and groin with soap and water. And if urine gets on your clothing, separate it from other clothes and wash the clothing right away. It’s important to follow these precautions after each Jelmyto (mitomycin) treatment because your body gets rid of the medication through your urine.
Jelmyto (mitomycin) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Some people who got treatment with Jelmyto (mitomycin) developed blockages in the urinary tract. Some blockages involved narrowing of the urethra, or the tube that carries urine out of the body. This can lead to swelling in the kidney. In clinical studies, some blockages happened within the first 3 months of treatment, and most required procedures to open up the urinary tract (e.g., stenting).
Let a healthcare professional or your urologist know right away if you have pain in the sides and lower back (flank pain), fever, or little to no urination. These might be signs of a blockage in the urinary tract. If this happens, you’ll probably need to take a break from Jelmyto (mitomycin) treatment. You might need a procedure to open back up the urinary tract.
Low blood cell counts can happen with Jelmyto (mitomycin) treatment. Having low platelet counts can put you at risk for bleeding, and having low white blood cells can put you at risk for infections.
Before each treatment, your urologist will check your blood cell counts from your blood tests to make sure Jelmyto (mitomycin) is safe for you to get. Your treatment will probably get delayed if your urologist notices that your blood counts are low. They also might make changes to your treatment plan.
Based on animal studies and on how the medication works, there’s a risk that Jelmyto (mitomycin) can harm an unborn baby. If you’re female and you’re able to become pregnant, use effective birth control during your treatment with Jelmyto (mitomycin) and for 6 months after your last dose. If you’re male and have a partner who could become pregnant, use effective birth control (e.g. condoms) during treatment and for 3 months after your last Jelmyto (mitomycin) dose.
The typical dose depends on the imaging test results of your urinary tract. Your urologist will use the imaging results to determine the amount of Jelmyto (mitomycin) to give.
In general, Jelmyto (mitomycin) is a 4 mg/mL gel that’s given once a week through a urinary catheter or nephrostomy tube for 6 weeks. The maximum dose is 15 mL (60 mg).
Your urologist will check to see whether the medication has worked well to treat your cancer 3 months after you started Jelmyto (mitomycin). Your urologist might decide to continue Jelmyto (mitomycin) once a month for up to 11 treatment sessions if the medication is working well for you.
Contraindications are specific health conditions or situations in which a person should not take a medication due to safety concerns. If you have any of the following conditions or if any of the following apply to you, let your healthcare provider know because Jelmyto (mitomycin) will not be safe for you to take.